CapsoVision (NASDAQ:CV) Stock Price Up 51% – Still a Buy?

by · The Cerbat Gem

Shares of CapsoVision, Inc. (NASDAQ:CV – Get Free Report) shot up 51% on Tuesday . The company traded as high as $10.99 and last traded at $10.99. 147,901 shares traded hands during trading, an increase of 32% from the average session volume of 111,696 shares. The stock had previously closed at $7.28.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e)” rating on shares of CapsoVision in a research note on Tuesday, December 2nd. Zacks Research raised CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. Roth Capital set a $7.00 target price on CapsoVision in a report on Tuesday, November 4th. Finally, Benchmark restated a “speculative buy” rating on shares of CapsoVision in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, CapsoVision presently has an average rating of “Moderate Buy” and an average price target of $6.00.

Read Our Latest Stock Analysis on CV

CapsoVision Stock Performance

The company has a 50-day moving average of $5.13.

CapsoVision (NASDAQ:CV – Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $3.54 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CapsoVision stock. Citadel Advisors LLC bought a new stake in shares of CapsoVision, Inc. (NASDAQ:CV – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned about 0.05% of CapsoVision at the end of the most recent quarter.

CapsoVision Company Profile

(Get Free Report)

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.

Further Reading